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Oncology/College of American Patholo-
gists (ASCO/CAP) guidelines. [ 5 ] 
 HER2-negative breast cancers (ER+/
PR+/HER2– group) constitute the most 
prevalent immunopathological subtype, 
representing more than 66% of all cases, 
followed by triple negative breast can-
cers (TNBC), which occur in about 19% 
of the cases. The remaining events are 
commonly HER2-overexpressing breast 
cancers either or not presenting ER/PR 
receptors. [ 4 ] 
 Currently in clinical practice, the pres-
ence of ER is considered a good indicator 
of overall outcome and is commonly used 
to identify tumors that may respond to 
anti-estrogen hormonal therapy targeting ER-dependent sign-
aling pathways. [ 6 ] HER2-overexpressing tumors used to be char-
acterized by a poor outcome, but with the advent of anti-HER2 
monoclonal antibodies targeting HER2-dependent signaling 
pathways, these results have improved. [ 6 ] Absence of PR, ER, 
and HER2 characterizes the TNBC subtype, which is known as 
the only subgroup lacking targeted therapeutic options. More-
over, this group presents the worst prognosis when compared 
to the other breast cancer groups due to its aggressive and 
metastatic nature, low response to existing therapies and high 
rates of relapse. [ 7 ] Generally, TNBC is associated with women 
of African-American ethnicity, with less than 40 years of age at 
the time of initial diagnosis and carrying BRCA1 (breast cancer 
1, early onset) gene mutations. [ 8–10 ] From a morphological point 
of view, approximately 90% of TNBC occurrences are invasive 
ductal carcinomas, whereas the remaining cases are classifi ed 
as apocrine, lobular, adenoid cystic, and metaplastic. [ 11 ] Curi-
ously, the prognosis of each class has shown to be distinct 
despite sharing the triple-negative phenotype. This heteroge-
neity has also been confi rmed by gene expression profi le anal-
yses of breast cancer datasets. These studies led to the identi-
fi cation of six distinct TNBC subtypes that include basal-like 1 
(BL1), basal-like 2 (BL2), mesenchymal-like (ML), mesenchymal 
stem-like (MSL), luminal androgen receptor (LAR) and immu-
nomodulatory (IM). [ 12 ] The diversity of TNBC in terms of gene 
expression subtypes and the repertoire of genetic events has 
been recently reviewed. [ 13 ] The intrinsic complexity of TNBC, 
usually resulting in distinct response of patients to therapy, sug-
gests the need for a further subdivision of this subtype from 
a clinical perspective. The identifi cation of specifi c molecular 
markers for TNBC subgroups would undoubtedly contribute 
to a more precise diagnosis, making the development of pre-
dictive biomarkers and targeted therapies possible. Although 
an optimal treatment for TNBC remains an unmet need, this 
 Triple negative breast cancer (TNBC) is a particular immunopathological 
subtype of breast cancer that lacks expression of estrogen and progesterone 
receptors (ER/PR) and amplifi cation of the human epidermal growth factor 
receptor 2 (HER2) gene. Characterized by aggressive and metastatic pheno-
types and high rates of relapse, TNBC is the only breast cancer subgroup still 
lacking effective therapeutic options, thus presenting the worst prognosis. 
The development of targeted therapies, as well as early diagnosis methods, 
is vital to ensure an adequate and timely therapeutic intervention in patients 
with TNBC. This review intends to discuss potentially emerging approaches 
for the diagnosis and treatment of TNBC patients, with a special focus on 
nano-based solutions that actively target these particular tumors. 
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 1.  Introduction 
 It is foreseen that, for 2015, breast cancer will be one of the 
most commonly diagnosed cancers, accounting for about 1.7 
million new cases and resulting in more than 580 thousand 
deaths in the US alone. [ 1 ] This complex and heterogeneous dis-
ease is characterized by distinct cellular origins, mutations, his-
tology, progression, metastatic potential, therapeutic response 
and clinical outcome. [ 2 ] Due to its heterogeneity, additional sub-
classifi cations of breast cancer have been proposed based on 
intrinsic histological, immunopathological, and molecular fea-
tures. However, only the immunopathological classifi cation has 
been shown to signifi cantly help clinicians in the therapeutic 
decision-making process. [ 3 ] The immunopathological classifi -
cation of breast cancer is based on the expression of estrogen 
and progesterone receptors (ER/PR) and amplifi cation of the 
human epidermal growth factor receptor 2 (HER2). Distinct 
combinations of the presence (+) or absence (–) of these recep-
tors permit the categorization of breast tumors into four indi-
vidual groups, namely ER+/PR+/HER2+; ER+/PR+/HER2–; 
ER–/PR–/HER2+; and ER–/PR–/HER2–, or triple negative. [ 4 ] 
Absence of ER/PR has been strictly defi ned as less than 1% 
expression by the most recent American Society of Clinical 
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review aims at discussing the potentially emerging approaches 
for its diagnosis and treatment, with particular emphasis on 
nanotechnology-based strategies. 
 2.  TNBC: Strategies for Diagnosis and Treatment 
 Signifi cant improvements in medical instrumentation com-
bined with recent advances in nanotechnology and synthetic 
biology have contributed to the progress of the oncology fi eld. 
Particularly, several nanocarriers and targeting agents are 
currently under investigation for delivering therapeutic and 
imaging agents at the tumor site towards an improvement of 
diagnosis and therapy. 
 2.1.  Current Scenario in the Diagnosis of TNBC 
 The aggressive and metastatic nature of TNBC makes its diag-
nosis particularly important and decisive to ensure an early 
and adequate therapeutic intervention. In clinical practice, 
breast cancer diagnosis generally relies on three main types of 
analyses: i) clinical examination through palpation; ii) radio-
logical exams, including mammography, ultrasonography, 
and magnetic resonance imaging (MRI); iii) pathological tests 
based on biopsies. [ 14 ] Mammography, the most widely applied 
radiological exam for breast cancer detection, uses low-energy 
X-rays to create images of patients’ breasts allowing the visu-
alization of abnormal tissue features. [ 15 ] However, clinical data 
indicate that most TNBC tumors lack the abnormal features 
of breast cancer, leading to an inaccurate diagnosis. [ 15,16 ] Com-
plementary exams, such as ultrasonography, should therefore 
be considered when evaluating patients with increased risk of 
TNBC. Ultrasonography allows the visualization of internal 
body structures through ultrasound images and typically pre-
sents a sensitivity higher than 90% for TNBC detection. [ 17 ] 
However, its accuracy is greatly dependent on the examiner’s 
experience and may be limited in case of tumors presenting 
benign image features. [ 15–17 ] MRI uses magnetic fi elds and 
radio waves to construct images of the body and has been 
more accurate in TNBC diagnosis. [ 15,16 ] Despite the essential 
role of radiological examination of suspicious breast cancer 
patients, it frequently results in false-positive fi ndings leading 
to unnecessary invasive biopsy analyses. [ 15 ] On the other hand, 
many early stage tumors remain unnoticed until they progress 
and fi rst symptoms, such as breast pain and nipple discharge 
appear. [ 15 ] Therefore, clinical identifi cation of TNBC currently 
relies on determining the absence of ER, PR, and HER2 in 
biopsy samples using standard immunohistochemistry (IHC) 
tests. [ 14 ] IHC analyses enable the detection of those cell recep-
tors through the use of antibodies that specifi cally bind to 
antigens present in the tissue samples. [ 14 ] Antibody–antigen 
binding is commonly visualized using chemical or enzy-
matic staining. [ 14 ] Several standards and recommendations for 
IHC analyses have been proposed by international experts to 
improve reproducibility and reliability of results amongst labo-
ratories. [ 5,18 ] In summary, IHC tests and critical examination 
by clinicians are the best available approaches to validate a 
TNBC diagnosis. 
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 2.2.  Novel Approaches for the Diagnosis of TNBC 
 Novel or optimized methods and biomarkers that provide une-
quivocal information about TNBC at early stages, as well as 
predictive indications about the therapeutic outcome have been 
pursued by both clinicians and researchers. Recent studies sug-
gested that positron emission tomography (PET) with 2-deoxy-
2-[fl uorine-18]fl uoro- D -glucose ( 18 F-FDG) could be a promising 
tool for the detection of TNBC and axillary lymph node metas-
tasis with a higher level of accuracy compared to other tumor 
subtypes. [ 15 ] PET is an imaging method that constructs three-
dimensional images by measuring radiolabelled tracer mol-
ecules in the body. [ 15 ]  18 F-FDG tracer, a glucose analogue, is 
taken up by cells and allows the identifi cation of regions with 
increased glucose uptake—a characteristic of tumor tissues. [ 15 ] 
This technique enables the detection of metabolic alterations 
even before morphological changes take place. [ 19 ] However, 
the use of  18 F-FDG–PET technique as a diagnostic tool for 
TNBC may be limited to metastatic stages due to the low FDG 
uptake in early breast cancers. [ 15 ] Although anatomic imaging 
techniques usually apply contrast agents (e.g. microbubbles or 
radioactive, fl uorescent, and bioluminescent probes) to improve 
the resolution of images, most are nonspecifi c, exclusively pro-
viding morphologic information or allowing tumor detection 
only in advanced stages. [ 20 ] 
 Advances in the synthetic biology fi eld have contributed to 
develop novel and specifi c contrast agents with potential molec-
ular imaging applications. [ 21,22 ] Briefl y, molecular imaging 
uses molecular probes to detect key biological processes by 
coupling signaling or contrast agents with ligands that target 
overexpressed or upregulated cellular receptors ( Figure  1 ). This 
approach allows the examination of tumors from a molecular 
rather than a morphological perspective. [ 23 ] Since molecular 
changes generally occur much earlier than morphological 
alterations, molecular imaging may be very promising for the 
detection of early stage tumors. However, from our perspective, 
the choice of the adequate targeting ligand is crucial for the 
success of the detection technique. 
 2.2.1.  Targeting Ligands 
 Antibodies, peptides, aptamers and other small molecules have 
been proposed as targeting ligands to be further combined with 
contrast agents used in imaging techniques. Their main fea-
tures, as well as examples of their potential in the detection of 
TNBC are discussed in this section. 
 Antibodies : Antibodies comprise the most studied class of 
targeting ligands. This class is characterized by single protein 
molecules containing two epitope binding sites that provide 
high selectivity and affi nity for target binding. [ 24 ] Advances in 
protein engineering have allowed the production of antibodies 
with desired features (e.g. size, specifi city, immunogenicity), 
depending on their fi nal use. [ 25 ] However, the relatively high 
production costs of antibodies, alongside with their problem-
atic conjugation to signaling agents, often restrict their appli-
cation. [ 24 ] Various antibodies have been proposed as suitable 
targeting ligands for conjugation with breast cancer molecular 
imaging probes. For instance, radiolabeled transtuzumab and 
pertuzumab antibodies targeting the HER2 cellular receptor 
entered clinical trials as imaging probes for PET and single 
photon emission computed tomography (SPECT) imaging 
modalities. [ 26 ] Moreover, anti-epidermal growth factor receptor 
(anti-EGFR) and anti-vascular endothelial growth factor 
receptor (anti-VEGFR) antibodies conjugated with fl uorescent 
nanoparticles and ultrasound contrast agents, respectively, have 
been assessed. [ 27,28 ] Using fl uorescence microscopy imaging 
and ultrasonography, these antibody-conjugated imaging agents 
showed the ability to effectively target breast 
cancer cells, enhancing the specifi city and 
sensitivity of the imaging techniques. [ 27,28 ] A 
few studies have demonstrated the utility of 
antibodies as targeting ligands for promising 
targets in TNBC models. Human antibodies 
specifi cally targeting the urokinase plasmi-
nogen activator receptor (uPAR), a target 
present in TNBC cells, demonstrated specifi c 
probe localization to the tumors using both 
optical and SPECT imaging after labeled 
with near-infrared (NIR) fl uorophores and 
Indium-111 ( 111 In), respectively. [ 29 ] More-
over, uPAR-targeted antibodies labeled with 
 111 In and Technetium-99m ( 99m Tc) showed 
improved detection sensitivity for bone and 
soft-tissue metastases compared to  18 F-FDG 
using PET imaging. [ 29 ] Shi et al. have also 
suggested the use of a tissue factor (TF)-tar-
geting antibody labeled with Copper-64 ( 64 Cu) 
in PET imaging after in vitro validation of fast 
tumor uptake in a TNBC model. [ 30 ] Although 
TF expression is upregulated in many solid 
tumor types besides TNBC, which makes this 
protein an interesting target from a clinical 
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gated to targeting ligands that are able to recognize specifi c cancer cell receptors.
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perspective, further studies need to be performed before this 
translation takes place. [ 30 ] The potential of antibodies as tar-
geting ligands transcends tumor detection purposes. Radiola-
beled antibodies could be extremely useful for both radioim-
munotherapy (RIT) and tumor monitoring during therapy. [ 31–33 ] 
To evaluate the potential of the anti-human B-B4 monoclonal 
antibody to target the syndecan-1 (CD138) antigen—corre-
lated with poor prognosis and aggressive phenotypes in breast 
carcinoma—a preclinical study on TNBC xenograft mice was 
performed. [ 31 ] Iodine-124 ( 124 I) and -131( 131 I) radiolabeled B-B4 
antibodies were tested for immuno-PET imaging and RIT, 
respectively. Immuno-PET using  124 I-B-B4 allowed the visu-
alization of CD138-expressing tumors. Mice treated with  131 I-
B-B4 RIT experienced partial or complete responses to therapy. 
These results reinforced the relevance of the B-B4 antibody for 
the diagnosis and treatment of metastatic TNBC. Scheltinga et 
al. have monitored downregulation of the insulin-like growth 
factor receptor-1 (IGF-1R) and VEGF expression in vivo in 
response to heat shock protein 90 (Hsp90) inhibition therapy 
using Zirconium-89 ( 89 Zr)-labeled MAB391 and bevacizumab 
for PET imaging. [ 32,33 ] These studies not only demonstrated the 
utility of  89 Zr-labeled antibodies in the visualization of IGF-1R 
and VEGF levels in vivo, but also showed their potential as bio-
markers for drugs targeting IGF-1R and VEGF expression. 
 Peptides : Peptide-based targeting agents are a promising 
class of low molecular weight ligands. They present high speci-
fi city and affi nity for target binding, low immunogenicity and 
reduced production costs. [ 34 ] In contrast to antibodies, peptides 
can target intracellular molecules. However, due to their small 
size, their biodistribution may be negatively affected when 
attached to signaling agents. [ 20 ] 
 The screening of Phage Display libraries has been widely 
used to discover target-binding peptides. [ 24 ] Phage Display tech-
nology consists in expressing peptide sequences fused to bac-
teriophage coat proteins through genetic engineering. [ 35 ] By 
inserting randomized DNA sequences into the bacteriophage 
genome, a variety of peptides (library) can be screened over sev-
eral rounds against the desired target (e.g. peptides, proteins 
or DNA sequences) using binding assays to identify target-
binding peptides. [ 24,35 ] Recently, a breast cancer-targeting pep-
tide was discovered using this technology. [ 36 ] The identifi ed pep-
tide, Cys–Leu–Lys–Ala–Asp–Lys–Ala–Lys–Cys (CK3), contains 
a C-end rule motif that is thought to mediate binding to the 
neuropilin-1 (NRP-1), a transmembrane protein that is overex-
pressed in diverse breast tumors and is usually associated with 
a poor outcome. The potential of the CK3 peptide as targeting 
ligand was validated by SPECT and near-infrared fl uorescence 
(NIRF) imaging techniques, which showed its accumulation in 
TNBC mice models. Crisp et al. rationally designed a distinct 
tumor imaging strategy based on activable cell-penetrating pep-
tides (ACPPs) targeting the matrix metalloproteinase (MMP)-2 
enzyme. [ 37 ] This approach takes advantage of the intensifi ed 
extracellular protease activity occurring in most invasive types 
of cancer. To amplify the specifi city and sensitivity of this 
strategy, the cyclic-RGD peptide was covalently linked to ACPP. 
This dual-targeted mechanism resulted in enhanced tumor 
uptake and contrast during fl uorescence imaging assays per-
formed in in vivo models of TNBC. [ 37 ] Additional characteris-
tics of the extracellular tumor environment, such as its acidic 
pH (6.2–7.0), have been exploited for specifi c targeting of 
imaging agents using peptides. Recently, a pH-responsive MRI 
nanoprobe was synthesized using a pH low insertion peptide 
(pHLIP) known to target tumor acidic pH. [ 38 ] As low pH is not 
observed in normal tissues, pHLIP-conjugated MRI nanoparti-
cles were specifi cally internalized by TNBC cells in vitro at pH 
6.5. Concomitantly, systemic delivery of the nanoparticles in 
a TNBC mouse model led to their accumulation in the tumor 
tissue, thus allowing its MRI detection. [ 38 ] 
 Aptamers : Aptamers are short, single-stranded DNA or RNA 
oligonucleotides with a unique 3D conformation that bind to 
specifi c target molecules with high affi nity. [ 39,40 ] This class of 
targeting ligands presents several advantageous features over 
antibodies, including low immunogenicity, high stability, easy 
production and modifi cation. [ 40 ] Target-binding aptamers can be 
selected through a screening process similar to Phage Display 
named Systematic Evolution of Ligands by Exponential Enrich-
ment (SELEX). [ 24,39 ] Aptamers displaying high affi nity and spec-
ifi city for desired target molecules (e.g. nucleic acids, proteins, 
sugars, and phospholipids) can be isolated from large libraries 
of randomized oligonucleotides over several rounds of selec-
tion. [ 39,40 ] Limitations include their susceptibility to degradation 
by nucleases and fast clearance. Nonetheless, these short oli-
gonucleotides have gained increasing attention for the develop-
ment of molecular probes. Their potential in targeting ligands 
for molecular imaging has been recently reviewed. [ 41 ] DNA 
aptamers specifi cally targeting triple negative metastatic tumor 
cells have been identifi ed using cell-SELEX methodology. [ 40 ] 
Preliminary imaging studies using a selected aptamer (LXL-1) 
revealed a 76% detection rate against metastatic breast cancer 
tissue and suggested that a cell surface membrane protein was 
the target. [ 40 ] The potential of a platelet-derived growth factor 
(PDGF)-binding aptamer conjugated to gold nanoparticles in 
the detection of PDGF overexpressing TNBC breast cancer cell 
lines has also been demonstrated. [ 42 ] The use of this aptamer as 
targeting ligand led to aggregation of gold nanoparticles in the 
cytoplasm of cancer cells, allowing the differentiation between 
cancer and normal cells using a dark fi eld optical microscope 
after photo-illumination. [ 42 ] Despite the rapidly growing interest 
in aptamers, with a few candidates already in preclinical and 
clinical trials for use as drugs, this class of molecules still needs 
to mature before its clinical translation as targeting ligands for 
molecular probes. [ 43 ] 
 Small molecules : Small molecule-based ligands (<500 Da) are 
an attractive class of targeting agents due to their vast diver-
sity in structure and properties, and relative low production 
costs. [ 21,24 ] However, only a few small molecules have been 
described as potential targeting agents for molecular imaging of 
tumors. The  18 F-FDG glucose analogue is the most widely used 
small molecule with clinical application in cancer imaging. [ 21 ] 
Ribofl avin and folate are examples of small molecules currently 
under investigation. [ 24 ] Targeted ligands based on ribofl avin can 
use the ribofl avin carrier protein (RCP), which is known to be 
upregulated in metabolically active cells, to target metaboli-
cally active cancer or endothelial cells. [ 24 ] Similarly, folate-based 
ligands can be used to direct imaging agents to tumor cells 
taking advantage of the folate affi nity for its receptors, which 
are known to be overexpressed in most tumors. [ 24 ] The potential 
of folate molecules to drive an ultra-small super-paramagnetic 
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iron oxide contrast agent (P1133) to cell folate receptors 
expressed in TNBC cells has been demonstrated both in vitro 
and in vivo. [ 44 ] P1133 particles were specifi cally internalized 
by folate receptor-expressing tumor cells, enhancing magnetic 
resonance images. [ 44 ] 
 2.2.2.  Image-guided therapy 
 Current primary goals of novel imaging strategies include the 
reduction of patient's exposure to radiation and the improve-
ment of exams resolution and specifi city. However, imaging 
agents may also play an important role in the development 
of image-guided therapies as alternative to surgery. Photo-
thermal, shortwave radiofrequency and alternating magnetic 
fi elds ablation techniques are examples of such therapies. [ 45 ] 
In all approaches, nanoparticles are activated by externally 
applied stimuli, namely NIR light, shortwave radiofrequency 
energy and alternating magnetic fi elds. [ 46–48 ] Gold nanoparti-
cles, carbon nanotubes and magnetic nanoparticles are among 
the most commonly studied nanomaterials for image-guided 
therapy. A few studies have evaluated the effi ciency of photo-
thermal ablation in TNBC cells both in vitro and in vivo using 
gold nanorods or nanoparticles irradiated with a NIR laser. [ 49,50 ] 
The results have shown a successful elimination of tumor cells 
by modulating the size and concentration of particles, power of 
the laser and irradiation period. [ 49,50 ] However, further investi-
gations should be carried out to evaluate the toxicity and speci-
fi city of these nanoparticles. Although a lot of work needs to be 
done to clarify the clinical relevance of these strategies, mul-
tifunctional approaches combining both imaging and thera-
peutic properties in the same nanoparticle are gaining interest 
and promise to revolutionize the breast cancer theranostics 
fi eld. 
 2.3.  Currently Approved and Emerging Therapeutic 
Routes for TNBC 
 For many years, breast cancer patients placed their hope 
uniquely in cytotoxic chemotherapy. Fortunately, over the past 
two decades, new target-directed approaches for breast cancer 
treatment have been developed and approved for clinical use 
( Table  1 ). The introduction of new therapeutic strategies led to a 
decline in the mortality rate by about 30% and an improvement 
of the 5-year overall survival rate to 90%. [ 52 ] However, life expec-
tancy for metastatic breast cancer patients is less optimistic, 
with a 5-year overall survival rate of only 24%. [ 53 ] 
 Currently, the therapy selected for each patient is dictated 
by the presence of cellular receptors for estrogen and pro-
gesterone hormones and human epidermal growth factor 2 
(HER2). [ 51 ] However, as patients with TNBC do not present 
those cellular receptors, the available therapeutic routes are 
more limited. In addition to surgery and radiotherapy, chemo-
therapy remains their only option. Cytotoxic combinations 
of anthracyclines and taxanes are commonly administered 
as fi rst-line treatment followed by capecitabine at the time of 
progression. [ 54–56 ] Anthracyclines (e.g. doxorubicin) are anti-
tumor antibiotics that interfere with enzymes involved in DNA 
replication, independently of the phase of the cell cycle. [ 57 ] 
Similarly, taxanes (e.g. docetaxel and paclitaxel) can damage 
cells in all cell cycle phases, but they act preferentially during 
the M phase by stopping the mitosis process or inhibiting the 
synthesis of proteins involved in cell reproduction. [ 58 ] Capecit-
abine is a prodrug of 5-fl uorouracil (5-FU) that belongs to the 
anti-metabolites class of drugs. [ 59 ] Generally, the 5-FU active 
form inhibits the RNA synthesis and its functions, as well as 
thymidylate synthase activity, and is incorporated into DNA 
causing strand breaks and damaging cells during the S phase 
of the cell cycle. [ 59 ] The limited treatment options available for 
TNBC together with its naturally aggressive behavior usually 
result in a worse prognosis compared to hormone or HER2 
receptor positive tumors. [ 51,60 ] Moreover, potential resistance to 
anthracyclines or taxanes also limits the choices for second- 
or further-line chemotherapy to a small number of non-cross-
resistant regimens. [ 60 ] Alternative chemotherapeutic agents, 
such as eribulin and ixabepilone—two non-taxane mitotic 
inhibitors—have raised hope for patients with metastatic 
TNBC. Eribulin has been shown to reduce the risk of death 
by 29% in patients previously treated with anthracyclines or 
taxanes, but it is even more effective in capecitabine pretreated 
patients. [ 61 ] Ixabepilone—an analogue of epothilone B—has 
been approved for advanced breast cancer treatment when 
combined with capecitabine after failure of anthracyclines and 
taxanes. [ 62 ] However, there are only a few prospective rand-
omized adjuvant trials addressing the TNBC subgroup. Most 
data have been retrieved from a retrospective subset anal-
ysis of larger trials including all types of non-HER2 positive 
breast cancer or from neoadjuvant trials. In general, approved 
agents for breast cancer therapy have resulted in improve-
ments of patient's outcome, but the prognosis for metastatic 
TNBC patients remains poor. Much work has been aimed at 
improving this scenario. Sunitinib and sorafenib—two anti-
VEGFR tyrosine kinase inhibitors—have emerged as potential 
candidates showing therapeutic activity in breast cancer trials 
with signifi cant TNBC populations. [ 63,64 ] Cetuximab—an anti-
EGFR monoclonal antibody currently approved by the Food 
and Drug Administration (FDA) and the European Medical 
Agency (EMA) for colorectal and head and neck cancers treat-
ment—has also shown activity in metastatic TNBC treatment 
when combined with cisplatin and carboplatin. [ 65,66 ] Moreover, 
DNA damage platinum-based regimens are gaining particular 
relevance in treating BRCA mutation-carrier patients since 
these genes are important regulators of DNA repair and con-
sequent maintenance of genomic stability. [ 67 ] Recent trials also 
suggested novel approaches for TNBC therapy based on agents 
that inhibit poly(ADP-ribose) polymerase (PARP), mammalian 
target of rapamycin (mTOR), phosphatidylinositol 3-kinase 
(PI3K), insulin-like growth factor (IGF), Hsp90 and histone 
deacetylase (HDAC) ( Figure  2 ). [ 51 ] However, evaluating their 
effi cacy is usually problematic as these trials have not been 
specifi cally designed for TNBC patients. 
 Nanotechnology-based drug delivery systems able to improve 
the therapeutic index of conventional anticancer agents have 
also been increasingly developed. [ 68 ] Such efforts have led to 
incredible advances, with nanomedicines evolving from simple 
passive tumor targeting carriers to multifunctional active tar-
geting vehicles. [ 69,70 ] 
www.MaterialsViews.com
www.advancedscience.com
R
EV
IE
W
1500053 (6 of 14) wileyonlinelibrary.com Adv. Sci. 2015, 2, 1500053© 2015 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
 2.3.1.  Nanocarriers 
 Nanomedicines for breast cancer can be applied in three dis-
tinct ways, namely through direct intratumoral delivery, pas-
sive targeting and active targeting. [ 45 ] Intratumoral delivery 
of nanomedicines confi nes their action to the tumor site. [ 71 ] 
However, as it requires direct injection guided by conventional 
imaging techniques, this strategy is limited to tumors that can 
be image-detected. [ 71 ] Passive targeting of nanomedicines relies 
on tumor-selective enhanced permeability and retention (EPR) 
effect characterized by an increased accumulation of macromol-
ecules in the tumor tissues. [ 72 ] This phenomenon results from 
distinct features of the tumor microenvironment, particularly 
the hyperpermeability of the tumor vasculature to macromol-
ecules and the enhanced fl uid retention in the tumor intersti-
tial space resulting from a dysfunctional lymphatic drainage 
system. [ 72 ] However, the diffi culty to achieve therapeutic drug 
concentrations at the tumor site may be a critical limitation for 
passive targeting. [ 73,74 ] Active targeting involves the conjugation 
of either monoclonal antibodies, peptides or aptamers to the 
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 Table 1.  Authorized medicines for breast cancer in the European Union (EU) by the European Medicines Agency (EMA), and in the USA by the Food 
and Drug Administration (FDA). 
Class Common name Trade name Condition Approval date Regulator
Mitotic inhibitors (non-taxanes) Eribulin mesylate Halaven Metastatic BC a) 
Locally advanced or metastatic BC a) 
11/2010
03/2011
FDA
EMA
Mitotic inhibitors (epothilones) Ixabepilone Ixempra Locally advanced or metastatic BC a) 10/2007 FDA
Mitotic inhibitors (taxanes) Albumin-bound paclitaxel Abraxane Locally advanced or metastatic BC a) 01/2008 EMA
Docetaxel Docetaxel Accord
Docetaxel Kabi
Docetaxel Mylan
Docetaxel Teva
Docetaxel Winthrop
BC a) 
BC a) 
BC a) 
BC a) 
BC a) 
05/2012
05/2012
01/2012
01/ 2010
04/2007
EMA
EMA
EMA
EMA
EMA
Taxotere BC a) 
Locally advanced or metastatic BC a) 
11/1995
05/1996
EMA
FDA
Anthracyclines Liposomal doxorubicin hydrochloride Caelyx
Myocet
Metastatic BC a) 06/1996
07/2000
EMA
EMA
Anti-metabolites Capecitabine Ecansya
Capecitabine Accord
Capecitabine SUN
Capecitabine Teva
Locally advanced or metastatic BC a) 
Locally advanced or metastatic BC a) 
Locally advanced or metastatic BC a) 
Locally advanced or metastatic BC a) 
04/2012
04/2012
06/2013
04/2012
EMA
EMA
EMA
EMA
Xeloda Locally advanced or metastatic BC a) 
Advanced BC a) 
02/2001
04/1998
EMA
FDA
Bisphosphonates Pamidronate disodium Aredia Bone metastases 08/1996 FDA
Tyrosine kinase inhibitors Lapatinib Tykerb HER2+ b) advanced or metastatic BC a) 03/2007
06/2008
FDA
EMA
Serine/threonine kinase inhibitors Everolimus Afi nitor ER+ c) /PR+ d) /HER2- b) advanced BC a) 08/2009
07/2012
EMA
FDA
Aromatase inhibitors Anastrozole Arimidex Advanced BC a) 01/1996 FDA
Letrozole Femara BC a) 
Advanced or metastatic BC a) 
07/1997
01/2001
FDA
FDA
SERMs e) Fulvestrant Faslodex ER+ c) metastatic BC a) 
ER+ c) /PR+ d) metastatic BC a) 
10/1998
02/1996
FDA
EMA
Tamoxifen Nolvadex ER+ c) metastatic BC a) 10/1996 FDA
Toremifene Fareston ER+ c) /PR+ d) metastatic BC a) 02/1996 EMA
Monoclonal antibodies Bevacizumab Avastin Metastatic BC a) 01/2005 EMA
Pertuzumab Perjeta HER2+ b) locally recurrent or metastatic 
BC a) 
HER2+ b) metastatic BC a) 
03/2013
06/2012
EMA
FDA
Trastuzumab Herceptin Early BC a) 
Metastatic BC a) 
08/2000
10/1998
EMA
FDA
(Ado)-trastuzumab emtansine 
(trastuzumab linked to DM1 drug)
Kadcyla HER2+ b) locally advanced or metastatic 
BC a) 
11/2013
02/2013
EMA
FDA
 a) BC: breast cancer;  b) HER2+/HER2-: human epidermal growth factor receptor 2 positive/negative;  c) ER+/–: estrogen receptor positive/negative;  d) PR+/–: progesterone 
receptor positive/negative;  e) SERMs: selective estrogen-receptor response modulators. [ 134,135 ] 
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surface of nanoparticles for specifi c binding to corresponding 
antigens or receptors in tumor cells. [ 45,75 ] This approach results 
in specifi c accumulation of nanomedicines at the tumor 
site. [ 45,75 ] In addition to minimizing systemic toxicity, nanomed-
icines can be tailored to offer diverse advantages over conven-
tional therapeutic agents:
•  Entrapment of poorly water soluble drugs, improving drug 
delivery; 
•  Transport of large therapeutic payloads; 
•  Controlled and sustained drug release, improving half-life in 
blood circulation; 
•  Enhanced internalization into the tumor via endocytosis, 
avoiding recognition by the P-glycoprotein and reducing fur-
ther drug resistance; 
•  Combined or multimodality therapy by co-delivery of two or 
more chemo-, radio-, thermo-, and biotherapeutic agents, 
promoting or avoiding their synergistic or antagonist effects, 
respectively; 
•  Visualization of drug delivery sites by co-delivery of therapeu-
tic and imaging agents. [ 45,70,76,77 ] 
 Despite all inherent benefi ts of using nanomedicines, special 
attention must be paid to aspects such as biodegradability, tox-
icity and immunogenicity of their constituents and metabolic 
products. [ 78 ] 
 Diverse formulations of nanomedicines 
with potential application in TNBC have 
been studied ( Table  2 ), with polymeric nano-
particles, polymeric micelles, dendrimers, 
viral nanoparticles, liposomes, carbon nano-
tubes and nanoconjugates as the most 
described in the literature. These systems can 
be used to deliver drugs, oligonucleotides, 
DNA or proteins. [ 79,80 ] 
 Besides the improved effects of targeted 
nanomedicines, their application in TNBC 
treatment is limited by the lack of known 
highly expressed tumor targets and by the 
development of corresponding ligands. [ 78,81 ] 
Molecular biology-based screening tech-
niques, such as Phage Display and SELEX, 
may play a catalytic role in the identifi cation 
of ligands that differentiate tumor cells from 
healthy ones, which can then be used to iden-
tify the target of interest. 
 Polymeric nanoparticles : Polymeric nano-
particles are vehicles with a diameter var-
ying from 50 nm to over 10 µm and made 
of natural or synthetic polymers. [ 82 ] Both 
hydrophilic and hydrophobic drugs, as 
well as proteins and nucleic acids, can be 
encapsulated into nanoparticles without 
chemical modifi cation. [ 82 ] Encapsulated 
agents are usually delivered at controlled 
rates over time or in response to the local 
environment. [ 82 ] Diverse release processes, 
such as surface or bulk erosion, diffu-
sion or swelling followed by diffusion are 
commonly observed. [ 69 ] Polymeric nanoparticles also offer 
the possibility to graft, conjugate or adsorb amphiphilic 
polymers at their surface, improving systemic circulation 
half-life. [ 83,84 ] Due to their interesting features, application 
of polymeric nanoparticles in cancer therapy has been exten-
sively studied. [ 69 ] They have been found to accumulate at a 
hundred times higher concentrations in tumor tissues com-
pared to those in normal tissues, maintaining drug levels in 
an optimum range for longer periods of time and increasing 
drug effi cacy. [ 85 ] Diverse studies on specifi c in vitro and in 
vivo models of TNBC have proven nanoparticle-encapsulated 
drugs (e.g. docetaxel, mitaplatin, and rapamycin) as effective 
as free drugs in inhibiting tumor growth even at low concen-
trations. [ 68,86,87 ] These observations indicate the possibility to 
reduce therapeutic dosages, thus decreasing the side effects 
on healthy tissues. [ 68,86,87 ] In addition to passive targeting, 
polymeric nanoparticles can be used to actively deliver cargoes 
at the tumor site when attached to specifi c ligands. A novel 
peptide (Gly–Ile–Arg–Leu–Arg–Gly) able to selectively rec-
ognize tumors expressing glucose-regulated protein GRP78, 
a radiation-induced cell surface receptor, has been identifi ed 
using Phage Display. [ 88 ] The conjugation of this peptide to 
polyester nanoparticles encapsulating paclitaxel induced apop-
tosis and delayed tumor growth in an irradiated xenograft 
mice model of TNBC, improving the therapeutic outcome 
compared to chemotherapy alone. [ 88 ] 
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 Figure 2.  Pathways, targets and emerging targeted agents in TNBC. VEGFR: vascular endothe-
lial growth factor receptor; EGFR: epidermal growth factor receptor; HSP90: heat-shock protein 
90; TK: tyrosine kinase; PI3K: phosphoinositide-3-kinase; PARP1: poly(ADP-ribose)polymerase 
1; PDK: 30-phosphoinositide-dependent kinase; MAPK: Mitogen-activated protein kinase; 
mTOR: mammalian target of rapamycin.
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 Polymeric micelles : Polymeric micelles are colloidal parti-
cles with a hydrophobic core and a hydrophilic shell typically 
presenting 5 nm to 100 nm in diameter. [ 79,80 ] Generally, they 
are formed by the assembly of hydrophobic and hydrophilic 
polymers in aqueous environments. [ 79,80 ] The micelles’ core 
results from Van der Waals bonds, which distribute the hydro-
phobic polymers symmetrically stabilized by the hydrophilic 
shell. [ 79,80 ] Due to their inherent amphiphilic properties, 
www.MaterialsViews.com
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 Table 2.  Promising nanomedicines for triple negative breast cancer (TNBC) therapy. 
Nanocarrier Active agent Targeting agent Target Ref.
Polymeric Nanoparticles
  
Docetaxel
EZH2 a) gene siRNA b) 
Mitaplatin
Rapamycin
None NA c)  [68] 
 [136] 
 [86] 
 [87] 
 [88] 
Paclitaxel GIRLRG d) peptide Glucose-regulated protein 78  [104] 
Polymeric Micelles
  
RL71
Docetaxel
None
Cetuximab
NA c) 
Epidermal growth factor receptor
 [93] 
Dendrimers
  
Antisense oligodeoxynucleotides (AODNs)
TWIST1 gene siRNA b) 
AODNs
None
Vascular endothelial growth factor
NA c) 
 [96 ]
 [97] 
Liposomes
  
Doxorubicin
Arsenic trioxide
eEF-2K e) gene siRNA b) 
Ferrocenyl tamoxifen
Doxorubicin and gemcitabine
Arsenic- and platinum-based drugs
Ceramide and sorafenib
None NA c)  [106] 
 [107] 
 [137] 
 [138] 
 [139] 
 [140] 
 [108] 
Rapamycin and doxorubicin LXY f) cyclic octapeptide Integrin alfa 3  [109] 
Carbon nanotubes
  
Temperature None NA c)  [123] 
Nanoconjugates
  
Morpholino antisense oligonucleotides 2C5 mAb h) 
Human TfR h) mAb g) 
Surface-bound nucleosomes
TfR h) 
 [121] 
 [78] 
Antisense oligonucleotides (AODNs) AODNs Epidermal growth factor receptor and and α4 
and β1 chains of laminin-411
 [122] 
Paclitaxel Ultra-small hyaluronic acid CD44 receptor  [119] 
 a) EZH2: enhancer of zeste homolog 2;  b) siRNA: small interfering RNA;  c) NA: not applicable;  d) GIRLRG: Gly-Ile-Arg-Leu-Arg-Gly;  e) eEF-2K: eukaryotic elongation factor 2 
kinase;  f) LXY: Cys-Asp-Gly-Phe(3,5-DiF)-Gly-Hyp-Asn-Cys;  g) TfR: transferrin receptor;  h) mAb: monoclonal antibody. 
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micelles can function as special vehicles for drug delivery. On 
one hand, the hydrophilic region makes micelles soluble in 
water, thus easily administrable intravenously, and avoids rapid 
uptake by the RES, improving circulation half-life. [ 89 ] On the 
other hand, the hydrophobic region can transport hydrophobic 
drugs loaded by physical encapsulation or chemical covalent 
attachment. [ 90 ] The potential of polymeric micelles to deliver 
anticancer drugs has been suggested in various preclinical and 
clinical studies. NK012, a poly(ethylene glycol)-poly(glutamic 
acid) (PEG-PGlu)-based micelle formulation carrying an iri-
notecan active metabolite (SN-38), has shown signifi cant anti-
tumor activity with no toxicity in several orthotopic tumor 
models by enhancing distribution and prolonging release of 
SN-38. [ 91 ] This candidate has entered phase II trials in patients 
with TNBC. [ 91 ] Styrene-co-maleic acid (SMA)-based micelles 
have also been used to deliver RL71—a hydrophobic second 
generation curcumin derivative with poor bioavailability—in 
various TNBC cell lines. [ 92 ] The improvement of drug solubility 
and pharmacokinetics resulted in a cytotoxicity profi le similar to 
the free drug. [ 92 ] Docetaxel has also been encapsulated into  D -a-
tocopheryl polyethylene glycol succinate (TPGS)-based micelles 
conjugated to cetuximab, a monoclonal antibody specifi cally 
binding to EGFR, to actively target EGFR-expressing TNBC cell 
lines. [ 93 ] This strategy demonstrated an increased therapeutic 
effect of targeted docetaxel compared to the free drug. [ 93 ] 
 Dendrimers : Dendrimers are synthetic macromolecules of 
nanometer dimensions (10 nm to 100 nm) formed by repeated 
units of branched monomers arising radially from a central 
core. [ 80,94 ] The preparation of dendrimers can be achieved by 
divergent (from the central core to the periphery) or convergent 
(from the periphery to the inner core) synthesis. [ 94 ] In both pro-
cesses controlled polymerization reactions are repeated, adding 
a precise number of terminal groups at each step or genera-
tion. [ 81 ] From the fi fth generation onwards, dendrimers present 
a cavity-enriched spherical shape, which make them unique 
vehicles for drug delivery. [ 95 ] Similarly to polymeric micelles, 
amphiphilic dendrimers with a hydrophobic core and a hydro-
philic periphery can be produced. In addition to therapeutic 
agents, targeting ligands or imaging compounds can easily be 
conjugated to the functional groups on the dendrimers sur-
face, increasing their functionality. [ 95 ] The ability of dendrimers 
to deliver gene silencing sequences has also been demon-
strated. [ 96,97 ] For instance, four-generation poly(amidoamine) 
dendrimers were constructed and conjugated to antisense oli-
godeoxynucleotides (AODNs) targeting the vascular endothe-
lial growth factor (VEGF). This approach increased the accu-
mulation of dendrimers into a TNBC-xenograft mouse model 
and inhibited the expression of VEGF, signifi cantly reducing 
tumor vascularization compared to the AODNs alone. [ 96 ] Finlay 
et al. also showed the ability of a modifi ed third generation 
poly(amidoamine) dendrimer to knockdown the TWIST1 tran-
scriptor factor and its associated target genes in TNBC cells uti-
lizing siRNA sequences. TWIST1 is commonly overexpressed 
in aggressive breast cancers and is involved in regulation pro-
cesses of cellular migration through epithelial-mesenchymal 
transition (EMT), which makes it a promising target for meta-
static TNBC. [ 97 ] 
 Viral nanoparticles : Viral nanoparticles are biological systems 
composed of proteomic and genomic complexes, with protein 
scaffolds typically packaging viral genetic information. [ 98,99 ] 
These nanoplatforms naturally occur in a variety of shapes 
(e.g. icosahedrons, spheres, and tubes) typically ranging from 
10 nm to over 1 µm. [ 98,99 ] The natural process of protein scaf-
fold formation by hierarchical self-assembly of individual pro-
tein subunits provides a simple means for drug loading, which 
constitutes one of the main advantages of viral-based nano-
carriers. [ 100 ] Furthermore, although only a few viruses show 
a natural affi nity for receptors that are upregulated in tumor 
cells, numerous chemical and genetic engineering techniques 
allow scientists to design viral particles able to target specifi c 
tumors. [ 80,99 ] Various types of virus, including adenovirus and 
adeno-associated virus, have been used for this purpose, but 
bacteriophages (or phages) are one of the most promising ones, 
due to their lack of tropism for mammalian cells. [ 101 ] Particu-
larly, fi lamentous bacteriophages have been extremely useful in 
the screening of homing peptides that target surface proteins 
of cancer cells via Phage Display for later use as targeting and 
imaging agents. [ 102,103 ] Moreover, due to their diversity and ver-
satility, these prokaryotic viruses have also been widely used as 
vehicles for gene and drug delivery. [ 99,104,105 ] Indeed, phages can 
be simultaneously engineered to display targeting ligands and 
to carry large payloads of cytotoxic drugs by chemical conju-
gation, acting as targeted nanomedicines. [ 104,105 ] The potential 
of fi lamentous phages displaying a host-specifi city-conferring 
ligand and carrying cytotoxic drugs has been demonstrated in 
breast cancer models. For instance, the use of bacteriophage-
based nanocarriers targeting HER2 overexpressing breast 
cancer cells showed a greater inhibition of the cell growth com-
pared to the corresponding free drugs. [ 104 ] Although, to our 
knowledge, no such vehicle has been specifi cally developed for 
TNBC therapy, we believe that this class of viral nanoparticles 
may give an important contribution to the fi eld. On one hand, 
Phage Display libraries could be used to screen peptides that 
bind specifi cally to TNBC cells, thus aiding the identifi cation 
of novel targets. On the other hand, bacteriophage-based plat-
forms containing identifi ed binding peptides and loaded with 
cytotoxic drugs could potentiate the drugs therapeutic effect by 
selectively destroying cancer cells while reducing side effects. 
This type of strategy is currently being studied by our research 
group. 
 Liposomes : Liposomes are spherical vesicles of up to 400 nm 
in diameter composed of lipids assembled in bilayers sur-
rounding an aqueous core. [ 79,80,94 ] Lipid spheres are spontane-
ously formed in aqueous environments as amphiphilic mole-
cules favor the contact of their hydrophilic groups with water 
molecules in an attempt to shield the hydrophobic ones. [ 94 ] 
Depending on solubility, drugs can be loaded either to the 
lipid membrane or to the aqueous core. [ 94 ] This feature makes 
liposomes versatile nanocarriers potentially able to improve 
drug biodistribution and pharmacokinetics. [ 79,94 ] Additionally, 
liposomes can behave as passive or active targeting agents, 
depending on the polymer moieties or targeting agents dis-
played on their surface. [ 99 ] Numerous studies have shown an 
enhanced antitumor activity of drug-carrying liposomes (e.g. 
doxorubicin, arsenic trioxide, ceramide and sorafenib) in xen-
ograft mice models of TNBC compared to the corresponding 
free drugs. [ 106–108 ] A recent study demonstrated the potential of 
liposomes to actively target integrin α-3 overexpressing-TNBC 
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models when attached to LXY (Cys–Asp–Gly–Phe(3,5-DiF)–
Gly–Hyp–Asn–Cys), a cyclic octapeptide. [ 109 ] This strategy led 
to the accumulation of co-administered drugs (doxorubicin 
and rapamycin) at the tumor site, resulting in an improved 
antitumor effi cacy. [ 109 ] Up to now, a few drug-loaded liposome 
formulations, namely EndoTAG-1 (paclitaxel) and MM-398 
(irinotecan), have reached clinical studies in patients with 
TNBC. [ 110,111 ] 
 Carbon nanotubes : Carbon nanotubes are cylindrical struc-
tures formed by benzene rings. [ 80 ] Depending on the number 
of cylindrical layers they are made of, carbon nanotubes can be 
classifi ed as single-walled (one layer) or multi-walled (multiple 
layers). [ 79 ] Single-walled nanotubes typically present 1 nm to 
2 nm in diameter and more than 50 nm in length. [ 79 ] The multi-
walled nanotubes’ diameter can range from 5 nm to 100 nm. [ 79 ] 
Naturally, carbon nanotubes are insoluble in any solvent, but 
they can be chemically modifi ed to become water-soluble or to 
incorporate any functional group. [ 79,80 ] The possibility of mul-
tiple functionalization of carbon nanotubes to bind a variety 
of molecules at once, combined with their unique biological 
and chemical features, makes them an advantageous vehicle 
for cancer therapy and imaging. [ 79,80,112,113 ] Both the size of the 
cylindrical structures and the number of walls can affect the 
mechanism of cellular uptake of nanotubes. [ 109–111 ] Usually, 
single-walled carbon nanotubes have the ability to penetrate 
into cells showing localized effects and prolonged distribu-
tion, whereas multi-walled carbon nanotubes are not incorpo-
rated by cells. [ 114–116 ] An interesting application of multi-walled 
carbon nanotubes for TNBC therapy based on photothermal-
induced ablation has been proposed. [ 117 ] By mediating hyper-
thermia, nanotubes promoted cell membrane permeabilization 
and necrosis, eradicating both tumor mass and breast cancer 
stem cells, which are typically resistant to conventional thermal 
approaches and are involved in tumor recurrence. [ 117 ] 
 Nanoconjugates : Nanoconjugates consist of nanoplatforms 
containing active functional groups covalently bound to thera-
peutic agents. [ 99 ] Recently, various monoclonal antibody- and 
polymer-drug conjugates with applications in targeted anti-
cancer therapy have been described. [ 118–120 ] Ultra-small hyalu-
ronic acid-paclitaxel nanoconjugates were able to target CD44 
cancer cell surface receptors and enhance the antitumor effi cacy 
and overall survival over free drug in a mouse model of breast 
cancer brain metastases. [ 119 ] Moreover, the multifunctionality of 
poly( β -L-malic acid) (PLMA) nanoplatfoms was demonstrated 
by simultaneous conjugation of antitumor nucleosome-specifi c 
monoclonal antibody 2C5, anti-mouse transferrin receptor 
(TfR) antibody, and morpholino antisense oligonucleotides 
(MASONs). [ 121 ] This approach allowed targeting of breast 
cancer cells, delivering the agents across the endothelial system, 
and inhibiting EGFR synthesis. [ 121 ] When applied to in vivo 
models of TNBC, this system was able to signifi cantly inhibit 
EGFR synthesis and stop tumor progression. [ 121 ] Ljubimova 
et al. also synthesized PLMA-based nanoplatforms covalently 
linked to antisense oligonucleotides targeting EGFR (AON EGFR ) 
and α4 (AON α4 ) and β1 (AON β1 ) chains of laminin-411—the 
tumor vascular wall protein and angiogenesis marker—com-
bined with TfR monoclonal antibodies for extravasation and 
targeted tumor uptake. [ 122 ] This strategy showed a synergistic 
effect of three AONs, compared to their isolated effect, leading 
to a signifi cant arrest of EGFR and laminin-411 synthesis and 
tumor growth without presenting side effects in TNBC xeno-
graft mice. [ 122 ] Recently, EC1456, a folate-drug conjugate, and 
IMMU-132, an antibody-drug conjugate, entered clinical phase 
studies in patients with various types of cancer, including 
TNBC subtype. [ 123 ] EC1456 comprises folate molecules bound 
to tubulysin B hydrazide, a cytotoxic agent, whereas IMMU-132 
consists of RS7, an anti-TROP-2 antibody, conjugated to the 
active metabolite of irinotecan drug (SN-38). [ 123 ] 
 2.3.2.  Predicting Response to Therapy 
 Monitoring the patient's response to therapy is a crucial step in 
a successful treatment to assure a timely alteration of the thera-
peutic regimen when improvements are not observed. More-
over, and as important as monitoring patients under treatment, 
is the prediction of their response to therapy even before drug 
administration. [ 124 ] In theory, predictive biomarkers identifying 
responsive patients to individual therapies will enable personal-
ized therapeutic approaches, avoiding unnecessary exposure of 
unresponsive patients and resulting in better outcomes of the 
responsive subgroups. [ 125,126 ] 
 Over the last years, several gene expression-based tests 
that help predicting the clinical outcome and recurrence in 
breast tumor patients have become commercially available. [ 127 ] 
For instance, Oncotype DX Breast Cancer Assay and Mam-
maPrint—are used by clinicians to determine the best treat-
ment for patients with early-stage breast cancer that may have 
spread to nearby lymph nodes, but not towards distant parts 
of the body. [ 128 ] Oncotype DX Breast Cancer Assay is a reverse 
transcription polymerase chain reaction-based test performed 
on paraffi n embedded tissue sections, whereas MammaPrint, 
a gene expression microarray analysis, is performed on fresh 
tissue samples. [ 128 ] However, such a prognosis test for meta-
static breast cancer patients including TNBC is still to be devel-
oped. In fact, biomarker-driven therapeutic approaches for 
TNBC remain an immature fi eld of research. 
 A couple of factors that may facilitate the development of 
predictive biomarkers have recently been suggested. On one 
hand, the assessment of biomarkers for currently available 
therapeutic agents should focus on features and mechanisms 
of each individual agent. [ 125 ] On the other hand, biomarkers 
for novel therapeutic agents must be developed simultane-
ously from the preclinical phase. [ 125 ] By associating the devel-
opment of biomarkers to the intrinsic biology of both disease 
and treatment, shorter periods from research to clinic may be 
necessary. [ 125 ] 
 Currently, a few biomarker-driven therapies targeting TNBC 
have been proposed. For example, a biological therapy with 
cetuximab and panitumumab monoclonal antibodies targeting 
EGFR has emerged. [ 66,128 ] High levels of EGFR are commonly 
found in TNBC and are clinically associated to poor prognosis, 
which makes EGFR both a potential target and predictive bio-
marker. [ 129–131 ] Mutations in the BRCA1 gene, involved in DNA 
repair, have also been evaluated as potential response bio-
markers of TNBC patients to DNA damaging agents and PARP 
inhibitors, as BRCA1 alterations are associated with up to 90% 
of TNBC tumors. [ 126 ] The expression of androgen receptor (AR), 
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although present in less than 35% of TNBC cases, may also rep-
resent a potential therapy-guiding target. [ 132,133 ] Bicalutamide, 
an AR antagonist, is already in phase II clinical studies. [ 132,133 ] 
Despite recent efforts, further work is needed to identify reli-
able and clinically relevant predictive biomarkers, as well as to 
develop techniques and reference values for their use. 
 3.  Challenges and Opportunities 
 IHC analysis of biopsy samples is so far the best available 
method for TNBC diagnosis, following the critical examina-
tion of patients performed by clinicians. However, when fi rst 
symptoms are detected, an effective treatment can rarely be 
provided. Molecular imaging techniques using targeting 
ligands to increase the specifi city of contrast agents repre-
sent a promising approach for the early detection of tumors. 
The success of this strategy is intimately dependent on the 
utilization of an adequate targeting ligand. Consequently, it 
is crucial to identify suitable targets expressed in early stages 
of tumor growth before developing any targeting agents. 
Despite the diversity of targeting ligands under investigation, 
the use of their specifi c receptors as biomarkers of TNBC still 
needs to be validated in relevant models before claiming their 
clinical signifi cance. Moreover, some issues, such as the high 
production costs of antibodies, the variable biodistribution of 
small peptides and the high susceptibility to degradation of 
aptamers, must fi rst be overcome before these strategies can 
be translated to clinical practice. When patients are diagnosed 
with TNBC, the only available therapeutic options, apart from 
surgery and radiotherapy, are nonspecifi cally designed cyto-
toxic agents, such as anthracyclines and taxanes. Further-
more, the potential resistance to these drugs commonly limits 
subsequent choices in case the initial treatment does not 
work adequately. Besides, various clinical trials are focusing 
on alternative therapeutic agents including drugs, antibodies 
and inhibitors, either alone or in combination, special atten-
tion must be paid to the population subset being studied. To 
assure a more accurate evaluation of drug-target interactions, 
novel trials should be specifi cally designed for selected pop-
ulations of TNBC patients carrying the target(s) of interest. 
The use of drug delivery strategies that actively target cellular 
receptors expressed by TNBC cells may contribute to improve 
the effi cacy of both conventional and innovative drugs by 
improving targeting and reducing systemic toxicity and drug 
resistance. Nanotechnology and synthetic biology have pro-
moted the development of several nanocarriers and targeting 
agents that enable the delivery of drugs at the desired targets. 
Despite the potential of targeted nanomedicines, only a few 
formulations (i.e. polymeric micelles, liposomes and nano-
conjugates) have reached clinical stages in the treatment 
of patients with TNBC. Engineering the appropriate drug 
delivery system is a complex process. Various relevant factors 
including biodistribution, pharmacokinetics, biodegradability 
and immunogenicity must be considered. Additionally, their 
performance depends on the simultaneous combination of 
the adequate drug, targeting agent and target population. Cur-
rently, the application of these strategies to TNBC populations 
is greatly limited by the lack of well known, highly expressed 
targets, as well as by the development of corresponding tar-
geting agents. 
 From our perspective, the most promising way to solve the 
TNBC equation would involve a combined approach to all 
variables, starting with the pathological and molecular char-
acterization of TNBC and tumor microenvironment looking 
for common patterns, followed by the construction of multi-
functional platforms able to image the drug delivery process 
and monitor the response to therapy. Several techniques that 
could help researchers in this process are currently available. 
For instance, Phage Display and SELEX technologies hold great 
promise to the search for novel targets. On the other hand, 
nanotechnology-based carriers offer the necessary versatility 
to allow the combination of both diagnostic and therapeutic 
agents in a unique platform. 
 4.  Conclusions 
 The lack of effective and safe therapeutic options for patients 
diagnosed with TNBC has been driving many research and 
clinical efforts in this fi eld. Particularly, various drug delivery 
and targeting agents are under investigation for delivering 
therapeutic and/or imaging agents at the target tissue. 
Although nanomedicines with potential application in TNBC 
are still in early stages of development, this class of medi-
cines has demonstrated capacity to overcome the constraints 
of current ineffective and cytotoxic therapies. Additionally, 
nanotechnology-based targeting ligands, such as peptides, 
aptamers and small molecules promise to contribute to the 
improvement of detection technologies, which are commonly 
a limiting step for a timely therapeutic intervention in this 
group of patients. Although further endeavors are still needed 
to validate the clinical relevance and feasibility of these nano-
based strategies, novel nanocarriers, either man-made (syn-
thesized) or of natural origin, should be equipped with ligands 
that specifi cally target TNBC-receptors and, preferably, con-
jugated with more than one anticarcinogenic compound to 
reduce occurrence of resistance and increase the success rate 
of the treatment. 
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